Company profile
iSpecimen Inc.
NASDAQ: ISPC · Healthcare · Medical - Diagnostics & Research
#802 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
29DFH 34DQ 24GM 29SS 22
v0.1 · 65/100 weight · provisional
↑ Piotroski F, growth stability · ↓ return on equity, revenue growth (YoY)
Methodology →Revenue TTM
$1.0M
Rev growth YoY (TTM)
-87.2%
Net income (FY)
-$10.5M
Employees
7
as of 2026-08-27
Market cap
$225.7k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M$1.9M2025
Net income-$10.5M-$10.5M2025
Operating income-$9.0M-$9.0M2025
Total assets$9.5M$9.5M2025
Liabilities$6.4M$6.4M2025
Equity$3.1M$3.1M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product90%
Shipping and Handling10%
By geography
Not disclosed.
The read
What is iSpecimen Inc.’s revenue?
iSpecimen Inc. booked $1.9M in FY2025 revenue, contracting 79% year over year — slower than 88% of Healthcare companies we track, at a -543.7% net margin.
Peers · Healthcare
Pressure BioSciences, Inc.——Lipocine Inc.48DTHC Biomed Intl Ltd.——Anteris Technologies Global Corp.32DLongevity Health Holdings Inc.22DVeltex Corporation50DNeighbors
Middlesex →Key facts
CEOKatharyn Field
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersWoburn, MA
ExchangeNASDAQ: ISPC
Employees7
IPO date2021-06-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.